|Chemical and physical data|
|Molar mass||265.360 g·mol−1|
|3D model (JSmol)|
|Melting point||114 to 116 °C (237 to 241 °F)|
|Solubility in water||Soluble in methanol and chloroform mg/mL (20 °C)|
|NY (what is this?)|
Esmirtazapine (ORG-50,081) is a drug which was under development by Organon for the treatment of insomnia and vasomotor symptoms (e.g., hot flashes) associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H1 and 5-HT2 receptors and antagonist actions at α2-adrenergic receptors. As of March 2010, Merck terminated internal clinical development program for esmirtazapine, for hot flashes and insomnia, for strategic reasons.
(TCAs and TeCAs)